The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial
European Journal of Cancer2015Vol. 51(10), pp. 1321–1330
Citations Over TimeTop 10% of 2015 papers
Linda Dirven, Martin J. van den Bent, Andrew Bottomley, Nelly van der Meer, Bronno van der Holt, Maaike J. Vos, Annemiek Walenkamp, Laurens V. Beerepoot, Monique C.J. Hanse, Jaap C. Reijneveld, Aja Otten, Filip De Vos, Marion Smits, Jacoline E. C. Bromberg, Walter Taal, Martin Klein
Related Papers
- → The relationship between quality of life and health‐related quality of life in young males with Duchenne muscular dystrophy(2017)14 cited
- → Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes(2011)5 cited
- → Bevacizumab Can Be Infused Safely Over 10 Minutes in Metastatic Colorectal Cancer(2014)
- Intracranial hemorrhage in patients treated with bevacizumab：Report of two cases(2011)
- → 921P Assessment of health-related quality of life in head and neck cancer patients treated with chemoradiation(2021)